Immatics, Celgene sign £1.3bn deal to develop cancer immunotherapies

This article was originally published here

Based in Germany, Immatics is a clinical-stage biopharma company engaged in the discovery and development of T-cell redirecting cancer immunotherapies. The German firm is expected to develop T-Cell

The post Immatics, Celgene sign £1.3bn deal to develop cancer immunotherapies appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply